Bionano Genomics (BNGO) Free Cash Flow (2017 - 2026)

Bionano Genomics has reported Free Cash Flow for 10 years, with the latest figure at -$5.7 million in Q1 2026.

• Quarterly Free Cash Flow fell 133.53% year-over-year to -$5.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$19.6 million (up 49.25% YoY) and the FY2025 annual result came in at -$16.3 million, up 74.63% from the prior year.
• Free Cash Flow retreated to -$5.7 million in Q1 2026 per BNGO's latest filing, from -$4.1 million in the prior quarter.
• Over five years, Free Cash Flow peaked at -$1.7 million in Q4 2024 and troughed at -$36.4 million in Q2 2023.
• A 5-year average of -$20.0 million and a median of -$26.6 million in 2023 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2024 and 2025: Free Cash Flow surged 94.45% in 2024, then tumbled 139.7% in 2025.
• Over 5 years, Free Cash Flow stood at -$36.1 million in 2022, then climbed by 13.95% to -$31.0 million in 2023, then soared by 94.45% to -$1.7 million in 2024, then plunged by 139.7% to -$4.1 million in 2025, then slumped by 37.63% to -$5.7 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$5.7 million, -$4.1 million, and -$5.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.